Radioactive bullet targets advanced prostate cancer in new trial
NCT ID NCT04506567
Summary
This study is testing a new radioactive drug called 225Ac-J591 for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. The first phase aims to find the safest dose and schedule, while the second phase checks how well it lowers PSA levels (a prostate cancer marker). The drug is designed to seek out and deliver radiation directly to prostate cancer cells throughout the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brooklyn Methodist Hospital - New York Presbyterian
Brooklyn, New York, 11215, United States
-
Weill Cornell Medicine
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.